1 / 29

Neuroendocrinal Tumors : A Case of Mistaken Identity.

Delve into the complexities of neuroendocrinal tumors, exploring diagnosis pitfalls, treatment strategies, staging, critical biomarkers, management options, and future therapeutic implications.

winstont
Download Presentation

Neuroendocrinal Tumors : A Case of Mistaken Identity.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Neuroendocrinal Tumors: A Case of Mistaken Identity. Mohamed Abdulla M.D. Professor of Clinical Oncology, Kasr El-Aini School of Medicine Cairo University. www.oncologyclinic.org mohamed.abdulla@oncologyclinic.org. Alexandria – EGSSO – 24/06/2010

  2. ?

  3. Objectives: • Basic Information. • Magnitude of The Problem. • Pitfalls in Diagnosis. • What is New in Therapeutic Strategies.

  4. Origin & Classification:

  5. Origin & Classification:

  6. Natural History: Indolent Indolent Aggressive Resistant to ttt • Clinical Manifestations are Vague. • Advanced & Metastatic at Presentation. • Complete Surgical Removal is Questionable. • The Available Therapeutic Options are not Effective. Cure Dismal Outcome

  7. Staging & Survival: Yao et al. JCO. 2008, 26(18)3063-72

  8. Staging & Survival: G 1 - 2 Yao et al. JCO. 2008, 26(18)3063-72

  9. Staging & Survival: G 3 - 4 Yao et al. JCO. 2008, 26(18)3063-72

  10. Neuroendocrinal Tumors: The Hassle

  11. Neuroendocrinal Tumors: Yao et al. JCO. 2008, 26(18)3063-72

  12. Neuroendocrinal Tumors: Yao et al. JCO. 2008, 26(18)3063-72

  13. Neuroendocrinal Tumors: Yao et al. JCO. 2008, 26(18)3063-72

  14. Neuroendocrinal Tumors: American Cancer Society. Cancer prevalence: how many people have cancer? Updated October 30, 2008. Accessed May 7, 2009.

  15. Neuroendocrinal Tumors: Increased Incidence?? Better Understanding??

  16. Critical Biomarkers:1. Plasma Chromogranin (CgA) • A Measure of Endocrine Tissues. • Non-Specific • False Positive Results: • Proton Pump Inhibitors. • Atrophic Gastritis. • Renal Impairment.

  17. Critical Biomarkers:2. Urinary 5-HIAA: Compromised Survival

  18. Looking at Neuroendocrine Tumors: • Octreoscan. • SPECT/CT Hybrid Imaging. • MIBG. • CT/MRI. • Endoscopic Ultrasound. • Capsule Endoscopy.

  19. Neuroendocrinal Tumors:Management:

  20. Neuroendocrinal Tumors:Conventional Medical Treatment: • Sterptozotocin. • Anthracyclins. • Flouroupyremidines. • Dacarbazine.

  21. Neuroendocrinal Tumors:Somatostatin analogues: Symptomatic Relief 60% sst1 sst2 sst3 sst4 sst5 Tumor Shrinkage 5% Anti-proliferative Effect Blocking of Hormone Synthesis

  22. Neuroendocrinal Tumors:Somatostatin analogues:PROMID Study (2009): • ++ PFS (15.6 vs 5.9 months). • SD in 67%. • Functioning and Non-Functioning Tumors.

  23. Neuroendocrinal Tumors:Molecular Events & Therapeutic Implications:1. Angiogenesis: vHL Gene Oxygenation Hypoxia Bevacizumab + Octreotid LAR INF + Octreotid LAR PFS 96% 68% Angiogenesis +++ VEGF

  24. Neuroendocrinal Tumors:Molecular Events & Therapeutic Implications:2. mTOR Inhibitor: Mammalian Target of Rapamycin Altered Metabolism Cellular Growth Resistance to Apoptosis Protein Synthesis ++ Proliferation Autophagy

  25. Neuroendocrinal Tumors:Molecular Events & Therapeutic Implications:2. mTOR Inhibitor: RAD 001 (Everolimus): • PR 13% • SD 74%. • DP 13%.

  26. Neuroendocrinal Tumors:Molecular Events & Therapeutic Implications:2. mTOR Inhibitor: RADIANT – 1 Advanced Chemo-Resistant Neuroendocrinal Tumors RAD001 RAD001 Octreotid LAR Radiological Response: 77% 84% PFS: 9.7 ms. 16.7 ms. > 50% reduction in > 50% of Patients

  27. Quiz?? Adenocarcinoma NET

  28. Final Take Home Message: • NET not rare. • Surgery is the Cornerstone in Curative Management. • Serum Biomarkers Are Still There to Share. • Tissue Markers Should be more Highlighted. • Molecular Targeted Therapies are The Hope for Tomorrow.

  29. Thank you

More Related